Sera Prognostics (SERA) Non-Current Deffered Revenue (2020 - 2021)

Sera Prognostics (SERA) reported Non-Current Deffered Revenue of $35000.0 for Q3 2021, down 82.5% quarter-over-quarter from $200000.0 in Q2 2021.

Sera Prognostics (SERA) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Sera Prognostics has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $35000.0 in Q3 2021.

For the quarter ending Q3 2021, Non-Current Deffered Revenue changed N/A year-over-year to $35000.0; the trailing twelve-month figure through Sep 2021 stood at $35000.0 (changed N/A YoY), and the FY2020 full-year result was $139000.0, changed N/A from the prior year.
Non-Current Deffered Revenue for Q3 2021 stood at $35000.0, down from $200000.0 in the prior quarter.
The five-year high for Non-Current Deffered Revenue was $200000.0 in Q2 2021, with the low at $35000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	-
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	512.79 Mn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Sera Prognostics	93.48 Mn	93.48 Mn	-28,000.00	-

Download Data